The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation

Volume: 16, Issue: 9, Pages: e71 - e72
Published: Sep 1, 2021
Abstract
In the phase 3 ACTIVE study (CTONG1706), apatinib plus gefitinib has been found to have a significant improvement in the primary end point of the study, progression-free survival, compared with placebo plus gefitinib in patients with advanced NSCLC and EGFR mutation in the first-line setting.1 This result is in line with preceding clinical studies investigating the efficacy of combination therapies with an EGFR-tyrosine kinase inhibitor (TKI)...
Paper Details
Title
The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation
Published Date
Sep 1, 2021
Volume
16
Issue
9
Pages
e71 - e72
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.